Haemonetics (NYSE: HAE) grants director 2,538 restricted stock units
Rhea-AI Filing Summary
Zane Ellen M reported acquisition or exercise transactions in this Form 4 filing.
Haemonetics Corporation director Ellen M. Zane received a grant of 2,538 restricted stock units under the company’s Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, and her direct common stock holdings total 21,911 shares after the award.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,538 shares
Net Buy
1 txn
Insider
Zane Ellen M
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1, F2 | 2,538 | -- | -- |
Holdings After Transaction:
Common Stock — 21,911 shares (Direct)
Footnotes (2)
- F1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
- F2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Key Figures
RSUs granted: 2,538 units
Holdings after grant: 21,911 shares
Vesting schedule: 100% after one year
+1 more
4 metrics
RSUs granted
2,538 units
Restricted stock units granted to director Ellen M. Zane on 2026-07-24
Holdings after grant
21,911 shares
Common stock directly owned by Ellen M. Zane following the award
Vesting schedule
100% after one year
RSUs vest 100% on the first anniversary of the grant date
RSU-to-share ratio
1 RSU : 1 share
Each RSU converts into one share of Haemonetics common stock upon vesting
Key Terms
restricted stock units, contingent right, Long-Term Incentive Compensation Plan
3 terms
restricted stock units financial
"The securities awarded are in the form of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each RSU represents a contingent right to receive one share"
Long-Term Incentive Compensation Plan financial
"issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Haemonetics (HAE) director Ellen M. Zane report?
Ellen M. Zane, a director of Haemonetics, reported receiving a grant of 2,538 restricted stock units. These RSUs were issued under the company’s Amended and Restated 2019 Long-Term Incentive Compensation Plan and increased her direct common stock holdings to 21,911 shares.
How many restricted stock units did Ellen M. Zane receive from Haemonetics (HAE)?
Ellen M. Zane received 2,538 restricted stock units from Haemonetics. The grant is reported as common stock with footnotes clarifying it is in RSU form, issued under the company’s Amended and Restated 2019 Long-Term Incentive Compensation Plan for long-term equity compensation.
When do Ellen M. Zane’s Haemonetics (HAE) restricted stock units vest?
The restricted stock units granted to Ellen M. Zane vest 100% on the first anniversary of the grant date. This means all 2,538 RSUs vest together after one year, subject to the terms of Haemonetics’ Amended and Restated 2019 Long-Term Incentive Compensation Plan.
What does each RSU granted to Ellen M. Zane at Haemonetics (HAE) represent?
Each restricted stock unit granted to Ellen M. Zane represents a contingent right to receive one share of Haemonetics common stock upon vesting. Once vested, each RSU converts into a single share, aligning her compensation with the company’s equity performance.